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Summary 45 
• Reasons for performing study: Few studies have investigated ovarian function in the mare 46 
undergoing porcine zona pellucida (pZP) immunocontraception despite reported ovarian dysfunction 47 
in other species. 48 
 • Objectives: This study aimed to describe ovarian function and oestrous cyclicity in pony mares 49 
following treatment with either the conventional pZP vaccine or a novel recombinant form of the 50 
vaccine derived from porcine ZP3 and ZP4 (reZP). In addition, the contraceptive efficacy of pZP 51 
versus reZP was assessed.  52 
• Study Design: Blinded, randomised, prospective clinical trial. 53 
• Methods: Mares (n=21) were randomised into three groups of seven: Group I received the pZP 54 
vaccine, with a booster five weeks later; Group II received the reZP vaccine, with a booster five weeks 55 
later; and Group III (controls) received two treatments, five weeks apart, of saline and adjuvant alone. 56 
Mares underwent weekly monitoring via trans-rectal palpation and ultrasound examination of the 57 
reproductive tract, with daily monitoring during oestrus. Data were collected over a 24 week period 58 
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coinciding with the physiological breeding season; treatments commenced in week four. Serum 59 
samples were obtained for antibody titres and ovarian steroid level analyses at seven day intervals. 60 
Cycling mares were bred via fresh semen artificial inseminations, over a maximum of two consecutive 61 
oestrous cycles, commencing five weeks post booster vaccination.  62 
• Results: Control mares cycled throughout the trial. Post treatment, six of seven pZP mares (86%) 63 
and one reZP mare (14%) had extended anoestrus that correlated with basal serum oestradiol and 64 
progesterone levels. All mares resumed cyclicity by ten months post treatment. Pregnancies were 65 
diagnosed in all controls, four reZP- (57%) and none of the pZP- immunized mares.  66 
• Conclusions: The current study demonstrates the reversible suppression of ovarian function in 67 
pony mares following treatment with pZP. The effect of the reZP vaccine on pregnancy outcome 68 
requires further investigation.   69 
 70 
Introduction  71 
Investigation of porcine zona pellucida (pZP) as an immunocontraceptive in the mare began over 72 
twenty years ago [1]. In contrast to immunocontraceptive vaccines targeting gonadotrophin releasing 73 
hormone (GnRH),  which cause reproductive quiescence [2], pZP has traditionally been associated 74 
with continued oestrous cyclicity [3]. The maintenance of reproductive behaviours has made the pZP 75 
vaccine the preferred immunological method of population control in species with complex social 76 
structures, such as the feral horse (Equus caballus) and African elephant (Loxodonta africana) [4; 5].  77 
Research on pZP as a human antifertility vaccine waned following evidence of ovarian dysfunction in 78 
non-human primates [6]. Similar effects are reported in the rabbit, dog and sheep [7-9]. In contrast, 79 
little evidence for interference with ovarian function has been reported in the mare. In a previous 80 
study, one year of pZP treatment was found to have no effect on ovarian function [1], however longer 81 
periods of contraception, specifically > three years, were associated with declining oestradiol levels 82 
and ovulation rates in feral horses of the USA [10; 11]. A subsequent study in the same population 83 
reported no association between the incidence of ovulatory failure in mares and their duration of 84 
treatment [12].  Recently, investigators demonstrated ovarian inactivity in 13 of 14 mares within four 85 
months of treatment with single-dose pZP vaccine formulations [13].  86 
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A recombinant zona pellucida vaccine may provide potential advantages when compared with native 87 
pZP vaccines that include production efficiency and the avoidance of contamination with non-ZP 88 
proteins [14]. Recently, recombinant vaccines based on the expression of porcine ZP3 and ZP4 in 89 
Eschirichia coli, hereafter referred to as reZP, were developed [15].  90 
The current study aimed to describe ovarian function and oestrous cyclicity in pony mares following 91 
treatment with either native pZP or reZP vaccines. In addition, the contraceptive efficacy of reZP in 92 
the mare was investigated. 93 
 94 
Materials and methods 95 
The study was approved by the University of Pretoria’s Animal Ethics Committee (V051-13).  96 
 97 
Mare management 98 
Twenty-one Nooitgedacht pony mares, aged between 3 and 14 years and of variable parity, were 99 
studied from October 2013 to March 2014, coinciding with the physiological breeding season in the 100 
southern hemisphere [16]. Inclusion criteria were non-pregnant status, good physical and 101 
reproductive health and no previous immunocontraceptive exposure. Ponies were housed in outdoor 102 
grass paddocks, with free access to water and Eragrostis tef grass hay. Clinical examinations were 103 
performed weekly and mares were weighed using an electronic scale during weeks 1, 8 and 25 104 
(Table 1).  105 
 106 
Vaccines 107 
Native pZP vaccine was prepared according to standard methods [1; 11] and supplied by Trumpeter 108 
Farms and Veterinary Servicea. Aliquots of 1 mg purified pZP in phosphate buffered saline (PBS) 109 
were transferred to glass vials and lyophilised, sealed and stored at 4°C. Before vaccination, each vial 110 
was reconstituted with 5 ml sterile injection water with a final protein concentration of 200 µg/ml. 111 
The reZP vaccines, TT-KK-ZP3 and bRNase-KK-ZP4, were supplied by Dr. Satish Kumar Gupta 112 
(Reproductive Cell Biology Laboratory)b. Porcine ZP3 (amino acid (aa) residues 20-344) was 113 
expressed as a chimeric fusion protein encompassing a promiscuous T-cell epitope of tetanus toxoid 114 
(TT; aa residues 830-844) at its N-terminus and separated from ZP3 by a dilysine linker (TT-KK-ZP3) 115 
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in E. coli [15]. Similarly, porcine ZP4 (aa residues 22-462) was expressed in E. coli as a chimeric 116 
fusion protein incorporating a promiscuous T-cell epitope of bovine RNase (bRNase; aa residues 94-117 
104; bRNase-KK-ZP4) [15]. Recombinant proteins were purified from inclusion bodies followed by 118 
refolding, as described previously [17]. Recombinant TT-KK-ZP3 and bRNase-KK-ZP4 were dialyzed 119 
separately in 20 mM Tris pH 6.0 and the respective protein concentration estimated using a BCA 120 
Protein Estimation Kitc and adjusted to 500 µg/ml.   121 
   122 
Study design 123 
Mares were stratified by age and randomly assigned to one of three treatment groups; the primary 124 
investigator was blinded to treatment assignment. Treatments were administered into the gluteal 125 
muscles, commencing in week four, as follows: 126 
Group I (n=7) received a primary vaccination (V1) consisting of 100 μg (0.5 ml) pZP emulsified with 127 
0.5 ml Freund’s modified complete adjuvant (FMCA). Five weeks later, a booster (V2) consisting of 128 
100 μg pZP emulsified with 0.5 ml Freund’s incomplete adjuvant (FIA) was administered into the 129 
contralateral hindquarter;  130 
Group II (n=7) received two primary vaccinations (V1), one on each side of the hindquarters, 131 
consisting of 250 μg (0.5 ml) recombinant ZP3 and ZP4 proteins respectively, each emulsified with 132 
0.5 ml FMCA. Five weeks later, two boosters (V2) consisting of the same doses of recombinant ZP3 133 
and ZP4 emulsified with 0.5 ml FIA, were similarly administered;   134 
Group III (n=7, control group) received an initial treatment (V1) consisting of 0.5 ml sterile saline 135 
emulsified with 0.5 ml FMCA. Five weeks later, a second treatment (V2) consisting of 0.5 ml sterile 136 
saline emulsified with 0.5 ml FIA was administered into the contralateral hindquarter. 137 
 138 
Trans-rectal monitoring of the reproductive tract 139 
Mares underwent examination by trans-rectal palpation and ultrasonography of the reproductive tract 140 
at seven day intervals. In cycling mares, examinations coincided with days 7 and 14 of consecutive 141 
oestrous cycles, with daily monitoring from day 14 until ovulation (day 0). Day 0 was defined by the 142 
ultrasonographic detection of a corpus luteum (CL), correlated to the absence of a dominant follicle 143 
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identified on the previous day. Ultrasound examinations were performed using a portable ultrasound 144 
machine (A6V)d and a 3–8 MHz linear array rectal probe. 145 
Ovarian dimensions were estimated digitally and recorded in three perpendicular planes. Ovarian 146 
volumes were calculated using the prolate ellipsoid formula (length x height x width x 0.523) [18]. 147 
Identifiable structures on each ovary were recorded and follicles ranked according to approximate 148 
diameter (< 15mm, 15 to 20mm, and 20 to 25mm). Follicles > 25 mm in diameter were individually 149 
measured from the ultrasonographic image of the follicle at its maximum, using the electronic calliper 150 
function of the ultrasound machine. The average of two perpendicular diameter measurements, one 151 
of which represented the widest diameter of the follicle, was recorded as the follicle diameter [19]. 152 
Anoestrus was defined as bilaterally small ovaries (both <25 cm3), scant follicular development and 153 
the absence of any follicles >15 mm in diameter [20]. 154 
 155 
Artificial inseminations 156 
All cycling mares were bred by artificial insemination (AI) over a maximum of two consecutive 157 
oestrous cycles using fresh semen collected from a single stallion of proven fertility, commencing > 158 
five weeks post V2.  Inseminations were performed according to standard practices once a mare’s 159 
ovulation was adjudged imminent, i.e. a pre-ovulatory follicle > 35 mm together with maximal or 160 
decreasing endometrial oedema [21]. Semen doses consisted of > 1 x 109 progressively motile 161 
spermatozoa, extended 1:1 in a pre-warmed skim-milk (MCT) mediume. Semen motility was 162 
evaluated subjectively under light microscopy. Semen concentration was quantified using a 163 
photometer calibrated for use with equine semenf. Inseminations were repeated if a mare failed to 164 
ovulate within 72 h. Pregnancy diagnoses by trans-rectal ultrasound examination were performed 14 165 
days post ovulation. If pregnant, mares were excluded from further breeding and sampling.  166 
 167 
Blood samples for hormonal assays and antibody titre determination   168 
Blood samples from all mares were collected by jugular venipuncture at seven day intervals. In 169 
cycling mares, sampling coincided with days 0, 7 and 14 of the mares’ oestrous cycles. Samples were 170 




Serum progesterone and oestradiol assays 173 
Serum progesterone and oestradiol levels were determined by means of radioimmunoassay (Coat-A-174 
Count progesterone and oestradiol)g [22]. Assay sensitivities for progesterone and oestradiol were 175 
0.06 nmol/L and 29 pmol/L respectively. For progesterone, intra- and inter-assay coefficients of 176 
variation were 6.1%, 3.5% and 4.7% and 10.3%, 4.3% and 5.2% for low, medium and high 177 
concentrations, respectively.  For oestradiol, intra- and inter-assay coefficients of variation were 7.0%, 178 
4.3% and 4.0% and 8.1%, 6.8% and 4.2% for low, medium and high concentrations, respectively. 179 
 180 
Antibody response 181 
Anti-ZP antibody response was measured by enzyme immunoassay (EIA), using a modification of a 182 
method previously described [2]. Briefly, 96-well plates (MaxiSorp)h were incubated at 2 – 8°C for 16 h 183 
with 1 µg purified pZP in 100 µl coating buffer (2.94% NaHCO3, 1.59% Na2CO3, pH 9.6) per well. 184 
Plates were washed with PBS containing 0.05% Tween 20 and then blocked with 0.03% BSA in PBS 185 
for 16 h at 2 – 8°C.  Plates were then incubated with serial dilutions (1:1000 to 1: 8000 for test 186 
samples and 1:1000 to 1:64000 for positive reference serum) of standard and test serum samples at 187 
37°C for one hour.  The positive reference serum consisted of pooled sera from all seven individuals 188 
in Group I at expected maximal antibody titre (four weeks post V2). Blank wells were used as 189 
negative controls. After washing, antibodies were detected by incubating plates with recombinant 190 
protein G-horseradish peroxidasei at 37°C for one hour. After further washing, plates were developed 191 
with trimethylene blue (SureBlueTM)k. The reaction was stopped by adding 50 µl 2M H2SO4 per well. 192 
Absorbance at 450 nm was measured using a microplate photometer (MultiskanTM FC)m.  193 
Antibody response was measured as the mean sample absorbance (minus blank) expressed as a 194 
proportion of the mean absorbance (minus blank) of the positive reference sample at the same 195 
dilution for each plate (1:2000; 1:4000; 1:8000). The overall proportion positive (PP) was calculated 196 
as the average value over the three dilutions. 197 
 198 
Monitoring injection sites 199 
All mares were monitored daily for visible lesions including heat and swelling, and weekly by palpation 200 
of the approximate injection sites. Transcutaneous ultrasonography of the injection site area was 201 
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performed when indicated by clinical findings. Monitoring continued following completion of the study 202 
as part of the routine care of experimental animals. 203 
 204 
Reversibility 205 
All mares underwent examinations at three and six months following the trial’s completion to monitor 206 
reproductive activity. Teasing of mares continued after the study period as part of their routine 207 
management.   208 
 209 
Statistical analysis 210 
Data were assessed for normality through the plotting of histograms, calculation of descriptive 211 
statistics, and the Anderson-Darling test for normality, which was performed in commercially available 212 
softwaren. Categorical data were compared among treatment groups using chi-square or Fisher exact 213 
tests in available freewareo. The maximum oestradiol values and mean progesterone values pre and 214 
post V2 were extracted for each mare and used for the statistical comparison among groups. 215 
Quantitative data satisfying the normality assumption were subsequently compared among groups 216 
using one-way ANOVA. Non-normal data were compared using Kruskal-Wallis tests followed by 217 
pairwise Mann-Whitney U tests with correction of P values for multiple post hoc tests. A linear mixed 218 
model was used to estimate the effect of treatment group and time on antibody responses measured 219 
as proportion of the positive control. Horse was included as a random effect to account for the 220 
repeated sampling design. Mixed effects models were analysed in commercially available statistical 221 
softwarep.   Bonferroni adjustment was used to adjust for multiple post hoc testing and significance 222 




Trans-rectal monitoring of the reproductive tract 227 
All mares demonstrated cyclic ovarian activity prior to V2, although one mare in Group II showed a 228 
period of anoestrus between normal oestrous periods prior to commencing treatment.   229 
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In Group I (pZP), one mare cycled regularly throughout the study period. Four mares demonstrated 230 
anoestrus within five weeks of V2 that persisted until the end of the study. One showed anoestrus 231 
from 12 weeks post V2 until study completion, while another cycled erratically, characterised by one 232 
brief period of oestrus between prolonged periods of anoestrus.  233 
In Group II (reZP), one mare entered anoestrus within five weeks of V2, persisting until study 234 
completion. The remaining six mares cycled regularly throughout the study period.  235 
In Group III (controls), six mares demonstrated regular cyclic activity throughout the study. One 236 
developed a persistent CL of unknown cause, which resolved spontaneously.  237 
By week 16 (seven weeks post V2, prior to any positive pregnancy diagnoses), left and right ovary 238 
follicle counts and maximum follicle diameters in Group I were significantly lower than Group III. There 239 
were no significant differences in Group II between either Group I or Group III for these data points, 240 
suggesting an intermediate effect (Table 2). 241 
 242 
Serum progesterone and oestradiol profiles 243 
Mean progesterone profiles of Groups I, II and III mares prior to and more than five weeks following 244 
booster vaccination (V2) are shown in Figs. 1 and 2, respectively. The mean progesterone 245 
concentrations pre- and post V2 for the three groups were: 20.4 versus 6.4 nmol/L (Group I), 20.8 246 
versus 19.0 nmol/L (Group II) and 24.8 versus 25.3 nmol/L (Group III). There were no significant 247 
differences in average progesterone concentrations between groups prior to V2 (P = 0.616), 248 
thereafter the change in average concentrations were significantly different among groups (P = 249 
0.048). Group I had the largest average difference in progesterone values but post hoc pairwise 250 
comparisons did not indicate significant differences with Groups II and III (P = 0.149 and P = 0.068, 251 
respectively).  252 
The mean for the maximum oestradiol concentrations measured pre- and post V2 for the three groups 253 
were: 42.0 versus 6.8 pmol/L (Group I), 37.1 versus 19.8 pmol/L (Group II) and 51.5 versus 27.1 254 
pmol/L (Group III). There were no significant differences in maximum oestradiol concentrations 255 
between groups prior to V2 (P = 0.566), thereafter the change in maximum concentrations in Group I 256 
was significantly lower than Group III (P = 0.014), but not between either Groups I and II (P = 0.159) 257 




Antibody response 260 
Samples from Group I and II mares prior to the first vaccination and Group III mares at all 4 sampling 261 
times (pre-treatment, post primary and post booster treatments with FCMA and FIA, respectively, and 262 
end of season), effectively negative serum controls, showed a mean OD of 0.0841 (± SD 0.0218). 263 
This mean was statistically no different from the mean of all blank wells (P = 0.209; independent t-264 
test). All samples following immunisation with pZP (Group I) or reZP (Group II) rendered ODs that 265 
were greater than this mean plus two standard deviations.  266 
Anti-ZP antibody response varied by treatment group (P < 0.001) and time (P < 0.001) with the time 267 
effect also varying by treatment (P<0.001). Group I was significantly higher than Group II (P < 0.001), 268 
with Group II significantly higher than Group III (P = 0.006; Fig. 3).  269 
 270 
Pregnancy outcome 271 
In Group I, only four inseminations were performed due to the paucity of oestrous cycles available. In 272 
Group II, one mare showed anoestrus throughout and could not be bred. A total of 11 and nine 273 
inseminations were performed in Groups II and III respectively. The proportion of pregnancies 274 
achieved in Groups I, II and III were 0%, 57% and 100% respectively. Comparison of these 275 
proportions for Groups I and III was significant (P < 0.001), with no significant difference detected 276 
between Groups I and II, nor Groups II and III (P = 0.07 and 0.2 respectively).  277 
 278 
Injection site reactions 279 
No lameness or pyrexias were recorded. Swelling and, or palpable changes in muscular density at 280 
injection sites were detected in 20/21 mares post treatment. Overt, sterile abscessation occurred in 281 
three mares, all from Group II. Ultrasonography performed at the end of the study showed lesions 282 
affecting > one hindquarter in 17 of the 18 remaining mares. Lesions varied from mild changes in 283 
muscular architecture to poorly marginated areas of complex echogenic pattern < 8 cm in width. A 284 
follow-up ultrasonographic examination three months later showed distinct improvement in the 285 
appearance of lesions in 11 of these mares.  286 
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   287 
Reversibility 288 
All mares that had demonstrated anoestrus following treatment had resumed oestrous cyclicity by ten 289 
months post V2, based on follow-up oestrous monitoring or teasing records.  290 
 291 
Discussion 292 
The traditionally-accepted mechanism of action of pZP in the equine involves, primarily, the 293 
interference of anti-ZP antibodies in sperm-zona binding, leading to contraception with continued 294 
oestrous cyclicity [1; 23]. The current study, however, demonstrated suppression of ovarian function 295 
in six of seven pony mares following pZP treatment, characterised by small, inactive ovaries and 296 
basal ovarian hormone levels. The discrepancy between our findings and that of an earlier report of 297 
unaltered oestrous cyclicity during short-term treatment of mares with conventional pZP vaccine [1] 298 
may be due to the higher pZP dose administered in our study (100 µg versus 65 µg pZP), selected to 299 
reflect the current dose administered to feral horses [24-26]. Our findings confirm recently-reported 300 
ovarian quiescence in mares treated with long-acting pZP vaccines [13], suggesting that suppressed 301 
ovarian function is not unique to long-acting formulations.  302 
Previous studies on the effects of pZP on behaviour and social structure in feral horse populations, at 303 
the same dose of pZP, suggested that treated mares show decreased harem fidelity and increased 304 
reproductive behaviours [27; 28]. These findings are inconsistent with the current study, in which the 305 
majority of mares showed anoestrus following treatment, implying that there would be an opposite 306 
change (albeit transiently) in reproductive behaviours. The absence of these behaviours can be 307 
attributed to both the significant decrease in follicular number and sizes and oestradiol concentrations. 308 
Follicle counts and maximum follicle diameters for Group II showed no statistically significant 309 
differences to either Groups I or III in week 16, despite significant differences between the latter two 310 
groups. This partial effect parallels Group II’s intermediate antibody titres post V2. The pZP vaccine 311 
comprises all three native porcine zona glycoproteins (ZP2, ZP3 and ZP4), whereas reZP comprises 312 
only ZP3 and ZP4. The lower antibody titres post V2 in Group II as compared to Group I may be due 313 
to the fact that the pZP vaccine will elicit an antibody response against ZP2 as well as ZP3 and ZP4, 314 
and the ELISA read-outs using pZP antigen will reflect the summation of antibody titres against ZP2, 315 
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ZP3 and ZP4. Ideally, antibody titres against purified ZP3 and ZP4 should be assessed to determine 316 
whether antibody titres are responsible for the intermediate ovarian response observed in Group II.       317 
Further studies, involving either the administration of higher doses of the recombinant vaccine or 318 
using native pZP as the primary injection followed by reZP booster injections, are warranted. A third 319 
possibility would be to increase the number of booster vaccinations. Recently, it was shown that two 320 
boosters of recombinant dog ZP3, instead of one, showed better contraceptive efficacy in female mice 321 
[31].  322 
An unexpected finding was the prevalence of injection site reactions, supporting Bechert et al. [13] 323 
who reported injection site reactions in 43% of treated mares. Our findings failed to support anecdotal 324 
reports of injection site reactions occurring less frequently when administered into the gluteal rather 325 
than the neck musculature [32; 33]. The current findings, including the sterility of overt abscesses, 326 
also contradict previous reports linking abscessation to remote vaccine delivery, presumed to result 327 
from darts transferring dirt and bacteria into the subcutaneous tissues [34]. Reports of injection site 328 
reactions in feral populations, described as abscessation, varied from 0-11.5% and were associated 329 
with either Freund’s Complete Adjuvant (FCA), FMCA or FIA [1; 33; 35-37]. Our use of domestic 330 
mares enabled closer inspection than can be achieved in a feral horse population. Although 331 
individuals from all groups showed lesions, Group II was particularly over-represented. This may be a 332 
result of either or both the double volume of FCMA and FIA in their vaccination protocol or the tetanus 333 
toxoid and bovine RNase linked to the ZP3 and ZP4 recombinant proteins, respectively. 334 
The contraceptive efficacy of the pZP vaccine was confirmed in this study, however the absence of 335 
oestrous cyclicity appears to be responsible for infertility to a larger extent than interference with 336 
sperm-zona binding. In addition to species differences in response, contamination with non-zona 337 
pellucida ovarian proteins has been proposed as a possible cause of ovarian malfunction in other 338 
species [29]. The latter cannot be completely ruled out for the pZP vaccine, although such 339 
contamination is impossible with the use of recombinant vaccines. Apart from oophoritis, a possible 340 
mechanism of ovarian suppression could be an interference with cellular communications between 341 
the developing oocyte and its surrounding granulosa cells, as a result of immune-mediated alterations 342 
to the zona pellucida. A family of proteins known as connexins is involved in oocyte-granulosa cell 343 
communication. Connexin gene-knockout mice were found to demonstrate suppressed ovarian 344 
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activity with a lack of tertiary follicular development, reminiscent of the findings of the current study in 345 
mares [30].  346 
All mares exhibiting anoestrus following treatment showed evidence of cyclic activity within ten 347 
months of V2 and confirms the reported reversibility of pZP vaccines [38]. In the current study, follow-348 
up examinations coincided partially with winter, thus the effect of seasonal anoestrous in biasing 349 
resumption of cyclicity remains undefined.     350 
 351 
Conclusion 352 
The current study demonstrates the reversible suppression of ovarian function in six of seven (86%) 353 
pony mares following treatment with the native pZP vaccine. No significant contraceptive effect was 354 
produced by the reZP vaccine, however further investigation of recombinant ZP vaccines, as an 355 
alternative contraceptive in the mare, is warranted.  356 
 357 
Manufacturers’ addresses 358 
aWinters, California, USA  359 
bNational Institute of Immunology, New Delhi, India 360 
cPierce, Rockford, Illinois, USA 361 
dSonoscape, Shenzhen, China  362 
eSection of Reproduction, University of Pretoria, Onderstepoort, South Africa 363 
fSpermacue; Minitube International, Tiefenbach, Germany 364 
gSiemens Healthcare Diagnostics, Los Angeles, California, USA  365 
hThermo Fisher Scientific, Roskilde, Denmark (Cat: NUN430341) 366 
iLTC Tech South Africa, Johannesburg, South Africa 367 
kKirkegaard & Perry Lab Inc, Gaithersburg, Maryland, USA (Cat: 52-00-03) 368 
mThermo Fisher Scientific, Waltham, Massachusetts, USA 369 
nMINITAB Statistical Software, Release 13.32, Minitab Inc, State College, Pennsylvania, USA 370 
oEpi Info, version 6.04, C DC, Atlanta, Georgia, USA 371 




Figure legends 374 
Fig 1. Graph showing mean weekly serum progesterone levels (SE bars) for each study group over 375 
three consecutive oestrous cycles prior to V2, where days 0, 7 and 14 of each cycle have been 376 
synchronised in time. 377 
Fig 2. Graph showing mean weekly serum progesterone levels (SE bars) for cycling mares in each 378 
study group over three consecutive oestrous cycles > 5 weeks post V2, where days 0, 7 and 14 of 379 
each cycle have been synchronised in time. Weekly data is depicted for non-cycling mares. 380 
Fig 3. Mean anti-ZP antibody response expressed as a proportion of the positive control (with SEM) 381 
for each treatment group at four successive time-points.  382 
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Table 1. Mare distribution according to parity, age (median, range), and body-weight (median, range) for each study group. 525 
Mare information 
Group I: pZP Group II: reZP Group III: controls 
P value 
(n = 7) (n = 7) (n = 7) 
Nulliparous 4 3 5 0.6 
Foaled within last 3 years 3 2 1 0.5 
Foaled > 3 years ago 0 2 1 0.3 
Age (years) 7 (4, 10) 8 (3, 13) 6 (3, 14) 0.8 
Body-weight (kg) at week 1 416 (360, 503) 396 (329, 433) 436 (360, 473) 0.2 
Body-weight (kg) at week 8 396 (352, 495) 405 (333, 433) 405 (361, 433) 0.6 
Body-weight (kg) at week 24 435 (382, 515) 439 (359, 467) 445 (369, 472) 0.7 
pZP = porcine zona pellucida vaccine, reZP = recombinant zona pellucida vaccine 526 
 527 
  528 
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Table 2. Results of trans-rectal monitoring of the reproductive tract for 21 pony mares prior to and following treatment with either pZP 529 
(Group I), reZP (Group II) or saline (Group III)  530 
  Group I (n = 7) Group II (n = 7) Group III (n = 7)  P valuesc 
 
Week 1b 
Left ovary volume (cm3) 150.6 (52.3; 401.7) 78.5 (4.2; 153.8) 83.7 (28.2; 627.6) 0.5 
 Right ovary volume (cm3) 28.2 (6.3; 83.7) 6.3 (1.6; 94.1) 100.4 (9.4; 585.8) 0.1 
 Left ovary follicle count 3 (0; 6) 3 (0; 6) 4 (2; 8) 0.4 
 Right ovary follicle count 3 (1; 6) 3 (0; 3) 5 (1; 7) 0.3 
 Maximum follicle diameter (mm) 30.3 (15.0; 56.1) 46.5 (0.0; 48.9) 45.1 (22.4; 55.8) 0.2 
 
Week 2b 
Left ovary volume (cm3) 58.6 (18.8; 150.6) 18.8 (4.2; 205.0) 50.2 (14.1; 131.8) 0.7 
 Right ovary volume (cm3) 28.2 (18.8; 78.5) 15.7 (4.2; 52.3) 18.8 (6.3; 418.4) 0.6 
Pre-treatmenta Left ovary follicle count 4 (3; 7) 2 (2; 4) 3 (1; 9) 0.3 
 Right ovary follicle count 4 (2; 6) 3 (2; 4) 3 (1; 6) 0.4 
 Maximum follicle diameter (mm) 33.2 (20.0; 56.4) 28.1 (15.0; 48.9) 31.8 (12.0; 66.9) 0.8 
 
Week 3b 
Left ovary volume (cm3) 62.8 (9.4; 267.8) 18.8 (2.1; 205.1) 33.5 (6.3; 267.8) 0.6 
 Right ovary volume (cm3) 18.8 (6.3; 78.5) 15.7 (6.3; 78.5) 25.1 (18.8; 179.4) 0.3 
 Left ovary follicle count 4 (0; 9) 2 (0; 4) 4 (1; 13) 0.9 
 Right ovary follicle count 3 (1; 8) 3 (0; 6) 7 (3; 10) 0.09 
 Maximum follicle diameter (mm) 42.1 (15.0; 49.2) 36.1 (15.0; 52.5) 34.5 (21.2; 49.1) 0.7 
 
Week 14b 
Left ovary volume (cm3) 23.5 (6.3; 78.5) 78.5 (18.8; 179.4) 78.5 (6.3; 94.1) 0.3 
 Right ovary volume (cm3) 12.6 (6.3; 78.5) 28.2 (18.8; 94.1) 18.8 (6.3; 50.3) 0.5 
 Left ovary follicle count 1 (0; 6) 1 (0; 4) 3 (1; 6) 0.5 
 Right ovary follicle count 1a (0; 5) 2a,b (0; 6) 6b (2; 9) 0.008 
 Maximum follicle diameter (mm) 15.0 (0.0; 36.5) 18.0 (0.0; 47.6) 30.2 (15.0; 46.5) 0.8 
 
Week 15b 
Left ovary volume (cm3) 18.8 (4.2; 131.8) 23.5 (6.3; 150.6) 58.6 (8.4; 153.8) 0.5 
 Right ovary volume (cm3) 9.4 (6.3; 28.2) 18.8 (6.3; 205,0) 25.1 (9.4; 153.8) 0.1 
Post treatmenta Left ovary follicle count 1a (0; 2) 3b (0; 8) 2a,b (0; 4) 0.02 
 Right ovary follicle count 1a (0; 4) 2a,b (0; 4) 5b (2; 7) 0.006 
 Maximum follicle diameter (mm) 10.0 (0.0; 48.3) 15.0 (10.0; 49.2) 25.0 (15.0; 42.3) 0.5 
 
Week 16b 
Left ovary volume (cm3) 23.5 (6.3; 50.2) 41.8 (18.8; 205.0) 131.8 (2.1; 205.0) 0.2 
 Right ovary volume (cm3) 12.6 (6.3; 31.4) 28.2 (6.3; 205.0) 25.1 (18.8; 153.8) 0.1 
 Left ovary follicle count 0a (0; 3) 2a,b (0; 4) 3b (0; 7) 0.04 
 Right ovary follicle count 0a (0; 2) 2a,b (0; 5) 5b (3; 8) 0.001 
 Maximum follicle diameter (mm) 0.0a (0.0; 22.0) 20.0a,b (0.0; 53.1) 40.3b (16.0; 53.4) 0.006 
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aAll data are reported as median (range). bIf more than one data point for a mare existed during a particular week, the data point exhibiting the 531 
greatest follicle diameter was included. cMedians without superscripts in common are statistically different at P < 0.05 after adjustment for multiple 532 
post hoc testing. 533 



